Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 18Triple Negative Breast Neoplasms 16Carcinoma, Transitional Cell 4Neoplasm Metastasis 3Carcinoma, Non-Small-Cell Lung 3Salivary Gland Neoplasms 2Lung Neoplasms 2Colorectal Neoplasms 2Brain Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Locally Advanced Non-resectable Breast Cancer 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Neoplasm, Residual 1Mouth Neoplasms 1Metastatic Urothelial Cancer 1Meningeal Carcinomatosis 1Lung Diseases 1Localized Muscle Invasive Bladder Urothelial Carcinoma 1Liver Failure 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1

Interventions

Bevacizumab 40Paclitaxel 35Carboplatin 28pembrolizumab 21Cyclophosphamide 15Specimen Handling 14Cisplatin 13olaparib 11Blood Specimen Collection 11niraparib 10fludarabine 10Magnetic Resonance Spectroscopy 9Drug Therapy 9liposomal doxorubicin 8Topotecan 8Taxes 8Gemcitabine 8Biopsy 8Fulvestrant 7Doxorubicin 6cemiplimab 5abemaciclib 5Surveys and Questionnaires 5Standard of Care 5Injections 5Fluorouracil 5Cytoreduction Surgical Procedures 5trastuzumab deruxtecan 4mirvetuximab soravtansine 4aldesleukin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Ovarian Neoplasms × sacituzumab govitecan × Clear all
NCT06040970 2025-12-02

Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer

Icahn School of Medicine at Mount Sinai

Phase 1/2 Recruiting
54 enrolled
Gynecologic

Ovarian Neoplasms, Uterine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡